17,261 trials
Ovarian Cancer
Primary: Progression-free Survival. Progression is Defined According WHO-criteria as Appearance of Any New Lesion or Increase of Existing Lesions by at Least 25% — 28.8 months
Malignant Solid Tumour · Gastroesophageal Cancer
Primary: The Incidence of Dose Limiting Toxicities (DLT) in Phase I Dose Escalation — 0; 0; 1 participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval at Steady State — 87.14; 85.15 pg*hr/mL
Head and Neck Cancer
Primary: Disease-free Survival — 57.3; 65.9 percentage of participants — p=0.05
Atrial Fibrillation · Mitral Valve Insufficiency · Mitral Valve Stenosis
Primary: Freedom From Atrial Fibrillation — 31.1; 61.8 percentage of patients
Pancreatic Neoplasms
Primary: Overall Response Rate (ORR) Based on Independent Radiological Review (IRR) — 35 percentage of participants
Breast Cancer
Primary: Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors…
Breast Cancer
Primary: Percentage of Participants With Best Overall Response (BOR) as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST…
Lymphoma, Non-Hodgkin
Primary: Progression-Free Survival (PFS) — 73 percentage of participants
Carcinoma, Non Small Cell Lung
Primary: Three-month Progression-free Survival — 11.1 percentage of participants
Prostate Cancer
Primary: Percentage of Participants With Physician Reported Rectal Toxicity ≥ Grade 2 During the First 2 Years of Radiation Treatment — 38 percentage of participants — p=0.9138
Knee Pain
Primary: Participants With Clinically Meaningful Improvement in Pain Severity (0-10 cm; Higher Score on Pain Scale is Worse) — 15; 9 participants
Breast Cancer · Breast Neoplasms
Primary: Number of Participants Who Were Successfully Accrued in the Study, as a Measure of Feasibility — 35 participants
Hepatitis C
Primary: Percentage of Participants With Sustained Viral Response (SVR) 12 Weeks After Completing All Study Therapy (SVR12) — 33.3; 89.3; 80.0; 89.5 Percentage of participants
Asthma
Primary: Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants — 0.57; 0.65; 0.37; 0.34 AER events/person-year — p=0.781